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Abstract: Dysphagia in inclusion body myositis (IBM) is common and associated with
increased mortality and morbidity due to aspiration pneumonia, malnutrition and dehydra-
tion. There is currently no consensus on treatment of dysphagia in IBM and outcomes are
variable depending on timing of intervention, patient preference and available expertise.
There is a paucity of research exploring the pathophysiology of dysphagia in IBM and
appropriate investigations. Increased knowledge of the aetiopathogenesis is likely to change
the approach to treatment as well as improve the quality of life for patients. This review
explores the epidemiology and pathophysiology of dysphagia in IBM and the currently
available treatment strategies.
Keywords: inflammatory myopathies, swallowing, epidemiology, pathophysiology,
treatment, diagnosis
Introduction
Inclusion body myositis (IBM) is the most common acquired muscle disease in
Caucasians over 50 years of age.1 The disease is characterised by progressive weak-
ening of selected muscle groups including the quadriceps, long forearm flexors and the
muscles of the oropharynx.2 Dysphagia is a frequent and potentially fatal complication
of IBM. Dysphagia in IBM patients is linked to medical complications including
malnutrition, dehydration, recurrent aspiration pneumonia and decreased quality of
life.3,4 Any intervention that improves swallowing function in IBM patients therefore
has the capacity to significantly improve quality of life, and potentially reduce the
medical complications and mortality associated with IBM.
Although some advances have been made in the treatment of IBM, particularly
in the areas of exercise and support of respiratory function, the management of
dysphagia remains a somewhat limited area of research. Although the first case of
IBM was described in 1967 in a 66-year-old man with chronic polymyositis and
mild dysphagia,5 it was not until 1988 when Wintzen and colleagues performed
myotomies in patients with IBM that dysphagia as a part of the clinical picture was
formally identified.6 Until recently, little attention has been given to dysphagia in
IBM. A Cochrane review in 2016 identified only one randomised controlled trial of
intervention for dysphagia in IBM and concluded that evidence was lacking for or
against any specific intervention for dysphagia.7
Many aspects related to diagnosis and treatment of dysphagia in IBM pose
challenges to management. In this review, we address the epidemiology of dyspha-
gia in IBM, the diagnosis of dysphagia in IBM, the latest concepts in the
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pathophysiology of dysphagia in IBM and the current
opinion on the optimal management of dysphagia in
IBM. We also discuss the importance of addressing dys-
phagia, the challenges as well as emerging approaches to
treatment.
Epidemiology of Dysphagia in IBM
The reported incidence of dysphagia in IBM is variable,
owing in part to the insidious nature of the symptoms as
well as patient selection methods (eg, case series, directed
questionnaire, clinical evaluation). The overall incidence
of dysphagia has been reported to be as low as 40%3,8,9
and as high as 80%.9–11 In an observational study of 40
IBM patients, 40% were found to incidentally have dys-
phagia at the time of diagnosis.12 However, when
a directed questionnaire specifically seeking symptoms of
dysphagia was utilised in a cohort with IBM, symptoms
were reported in 80%11 In a retrospective study of 526
cases of oropharyngeal dysphagia, muscle disorders
accounted for 5.7%, with two thirds of these noted to be
due to inflammatory myopathy.13 IBM patients demon-
strate the most severe and frequent dysphagia compared
to other inflammatory myopathies.14
These prevalence figures are however almost certainly
an underestimate.11,15,16 In a study performed by Schrey
and his colleagues, dysphagia was either ignored or not
recognised and therefore not treated in seven of the 25
patients with IBM.15 Similarly, Cox and his colleagues
reported poor correlation between complaints of dysphagia
and abnormalities on Videofluroscopic Swallow Studies
(VFSS).11 Patients who denied dysphagic symptoms
were found to have marked abnormalities on VFSS.11
Murata and his colleges examined two cohorts of patients
with IBM: those reporting dysphagia and those reporting
no dysphagia.17 In VFSS studies pharyngeal propulsion,
defined as cricopharyngeal achalasia, was observed across
all of the trial participants reinforcing that dysphagia
occurs sub-clinically in IBM patients who may not report
swallowing impairments.17
Dysphagia in IBM patients is typically diagnosed late
in the course of the disease after limb weakness has been
established.18 The poor outcomes of treatment in dyspha-
gia may be attributed to the advanced stage at presentation.
Though it is viewed as a late complication of IBM, dys-
phagia does not appear related to disease severity and can
in some cases be a presenting symptom.4,6,9,11,19–22 The
incidence of dysphagia as a presenting symptom is as high
as 50%4 and as low as 10%12 In one case series dysphagia
was the presenting symptom in 15% of cases and predated
other manifestations by up to 10 years.3 Recently, Shibata
and his colleagues described a case of IBM where dyspha-
gia was the isolated presenting symptom for a period of 5
years prior to the onset of any other muscle weakness.23
While there are marked differences in the reported
incidence and timing of presentation of dysphagia, it is
evident that dysphagia is a common manifestation of IBM.
There is a need for further epidemiological surveys to
determine whether the varying differences in incidence
and timing of presentation of dysphagia in IBM are related
to how they are detected in different clinics, or whether the
differences are real and due to genetic or other aetiological
factors. It is important for clinicians to consider IBM as
a differential diagnosis in patients over 50 years who
present with dysphagia that is thought to be due to neuro-
muscular weakness.
Pathophysiology of Dysphagia in IBM
Characterising the pathophysiology of dysphagia in IBM is
desirable for diagnostic purposes as well as targeting specific
management. There is a paucity of research investigating the
pathophysiology of dysphagia specific to IBM. More often it
has been included as part of broader inflammatory myopathy
studies. Whilst there is significant symptom overlap, patients
with IBM demonstrate more severe and frequent
dysphagia11,14 and it is associated with poorer outcomes
and higher risk of aspiration pneumonia.4,6,11,14,17,24,25 This
is further complicated by subclinical dysphagic processes
and non-recognition by clinicians and patients, hindering
early detection and intervention.11 Having a clear under-
standing of the aetiopathogenesis of dysphagia specific to
IBM will result in improved understanding of physiology
and targeted approach to detection and management, in turn,
improved patient outcomes.
Initially, it was thought that the underlying aetiopathogen-
esis of dysphagia in IBM was due to spasm of the upper
esophageal sphincter (UES) as a result of hyperplasia or
hypertrophy of the cricopharyngeus muscle.25–27 Subsequent
studies indicated that reduced UES opening is a constant
clinical feature.4,11,14,17,26,28–30 Various causes may account
for this in IBM including fibrosis of cricopharyngeal
muscle,31 suprahyoid muscle weakness,14 diminished des-
cending bolus forces30 and impaired relaxation or spasm of
UES.31 One study using combination VFSS and manometry
indicated both suprahyoid and pharyngeal muscle weakness
were responsible for impaired UES opening in IBM rather
than cricopharyngeal spasm as previously suggested.14 With
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our current understanding of IBM and the effect on skeletal
muscle perhaps this makes more sense.
Reduced UES opening can lead to pyriform fossa
stasis30 being reported by the patient as the sensation of
food stuck in the throat, resulting in the need to swallow
repeatedly.9,11,28 Additionally impaired pharyngeal muscle
contraction,11,17,29,30 pharyngeal weakness,14,17,28,29
decreased epiglottic deflection,17,29 impaired laryngeal
elevation,4,11,14,31,32 reduced tongue control and poor
base of tongue retraction28 have also been implicated in
dysphagia in IBM. However, a recent study using MRI
imaging of 20 patients did not report impaired laryngeal
elevation.10
Evidence of aspiration on VFSS is high in IBM with
figures ranging from 35% to 58%.11,15,28 This variability
regarding the timing, amount and source of aspiration
warrants further investigation. In two studies involving
23 and 35 patients with IBM evidence of aspiration was
reported in 35% and 53%, respectively.11 A more recent
study of 25 cases reported aspiration in 58% of patients
and frank aspiration pneumonias in 25% of patients.15
Despite the number of analysed cases roughly being the
same amongst these three studies, there is a notable dif-
ference in the reporting of aspiration and figures are most
likely to be within 50–60%.
The majority of dysphagia in IBM research has
focussed on the oro-pharyngeal phase of swallowing.
However, one study of 4 patients highlighted oesophageal
striated muscle involvement leading to oesophageal dys-
phagia characterised by a reduction of upper esophageal
peristalsis and low UES pressures.33 This area also war-
rants further investigation.
On a histopathological level, like in the limb muscles,
the cricopharyngeal muscle biopsies have both an inflam-
matory response and degenerative changes including
rimmed vacuoles.13,25–27 It has been suggested that inflam-
mation contributes to reduced compliance of the sphincter
and therefore impedes the opening of the UES.11,26,29 It is
interesting to note that whilst the histology between the
cricopharyngeal muscle and limb muscles are identical, the
pathological outcome of the cricopharyngeal muscle is
hyperplasia and hypertrophy rather than atrophy as
observed in the limb muscles. There is a need for more
research to investigate the underlying reasons behind this
phenomenon.
The definitive pathophysiology of dysphagia in IBM is
yet to be elucidated. Understanding the pathogenesis of the
disordered swallow in IBM will, in turn, help to identify
more suitable targets for treatment of dysphagia.34
Collectively, it is evident that pathophysiology lies signifi-
cantly but not solely within the oro-pharyngeal stage of
swallowing.
Diagnosis of Dysphagia in IBM
The diagnosis of dysphagia can be difficult as the clinical
course of IBM varies between patients including site of
onset, rate of progression of weakness and extent of mus-
cle weakness and atrophy. Dysphagia is a manifestation of
the systemic disease and not a disease isolated to the
oropharynx, although as stated above, it may start in this
muscle group. Dysphagia in IBM may manifest as
a feeling of stasis, it is reported as a need to swallow
repeatedly, a need to wash solids down with liquids, regur-
gitation, or choking.28,32,35 There is often a delay in the
diagnosis of dysphagia in IBM,13 and there a number of
reasons for this.
Due to the insidious nature of their disease, IBM
patients often become accustomed to minor difficulties
swallowing over many years/months, and other issues
seem more functionally important, so therefore unless
prompted, they do not report it unless it is severe and
progressive. Cox et al suggested that the two most sensi-
tive questions to detect dysphagia history in IBM are11,15
“Does food get stuck in your throat?” and “Do you have to
swallow repeatedly to get rid of food?”11
In addition, patients may have marked swallowing
abnormalities on investigation but be asymptomatic.17
Incomplete opening of the UES and pharyngeal propulsion
defined as cricopharyngeal achalasia occurs early without
warning signs and was observed in all IBM patients, even
those who did not report any difficulties with their swal-
lowing function in the Murata et al study.17 The under-
lying process of this dysfunction may be due to
inflammatory involvement of the cricopharyngeus and
pharyngeal constrictor muscles early in the disease.
Investigations of Dysphagia in IBM
Dysphagia can be diagnosed by clinical history and con-
firmed instrumentally by VFSS and flexible endoscopic
evaluation of swallowing (FEES). Manometry and MRI
imaging are currently not used in routine clinical practice
but may have the potential to aid diagnosis. Clinical his-
tory with specific questioning, using Cox et al11 screening
questions above, may identify difficulty with swallowing
but instrumental analysis is required to characterise the
temporal disruption of swallowing coordination and
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identify the underlying mechanisms involved. Instrumental
analysis is considered the gold standard in the diagnosis of
dysphagia and should be considered in all IBM patients
whose clinical history suggests some swallowing difficul-
ties (refer to Figure 1).
VFSS adequately assesses all phases of the swallow and
allows the anatomy and physiology of patient’s oropharyngeal
dysphagia to be defined.36 It is an adequate assessment for
swallowing function, penetration and aspiration risk. Themost
common VFSS abnormalities in IBM reported by Oh and his
colleagues4 include impaired tongue base retraction, crico-
pharyngeal dysfunction, decreased laryngeal elevation and
pharyngeal pooling. These findings have been reproducible
in multiple studies looking at dysphagia in IBM11,14,17,32,37
and therefore yield reliability. Videofluroscopic abnormalities
are common in IBM patients and were noted to be as high as
72% in the Langdon et al paper.14 The recent introduction of
objective measures and normative data for VFSS16 will ensure
more specific data regarding progression rates and a move
towards dysphagia staging in IBM. The major disadvantage of
videofluoroscopy imaging is radiation exposure.38
In FEES, a laryngoscope is passed transnasally to the
hypopharynx to view the larynx and pharynx.36 Food and
drinks are dyed to aid visualization of the bolus.36 FEES
allows an assessment of the anatomy, secretions and phar-
yngeal phase of the swallow.16,30 Vallecular and hypophar-
yngeal stasis of both secretions and bolus can be observed
and rated accordingly.16 Both VFSS and FEES can diagnose
aspiration and penetration reliably. The FEES registry
study39 showed that FEES was safely and efficaciously
used in a large cohort of patients with different diagnosis,
among them 29 patients with myopathies.39
Manometry can quantify the strength of pharyngeal
contraction, the completeness of UES relaxation, and the
relative timing between these two events. According to Oh
et al28 pharyngoesophageal manometry findings included
low amplitude pharyngeal constrictor contraction (75%),
normal resting tone and relaxation of the UES (82%), and
diminished inferior oesophageal sphincter pressure
(42%).28 These manometry findings have been reproducible
in multiple studies.13,14,17 Concurrent use of pharyngeal
manometry with video fluoroscopy can further delineate
underlying pathology and direct treatment modalities.14
Recent literature focuses on the use of novel real-time
MRI (RT-MRI) which is as reliable as VFSS and FEES for
evaluating swallowing in IBM patients.38,40 A study con-
ducted by Carstens and his colleagues using the RT-MRI on
22 patients found that IBM patients were more comfortable
with RT-MRI than VFSS or FEES imaging modalities.38,40
An advantage of the RT-MRI is that it provides additional
information such as quantitative functional and morphologic
pathologies, which are not provided by VFSS or FEES
methods38,40 and there is no radiation exposure.
Instrumental assessment is currently considered the gold
standard in the diagnosis of dysphagia and should be consid-
ered in all IBM patients whose clinical history suggest some
swallowing difficulties.VFSS is reasonable as an initial assess-
ment and will assess for swallowing dysfunction, aspiration
risk and penetration events. The use of manometry as
a diagnostic tool following VFSS analysis allows the under-
lying mechanism of the dysphagia to be delineated.
Information such as pressure response of UES, timing and
strength of pharyngeal contraction, UES relaxation and the
relationship between these events from manometry will, in
turn, direct the appropriate treatment modality (particularly if
considering an invasive treatment option). Following the pro-
mising recent research, there is potential for this to change in
the future with RT-MRI imaging to be utilised as both
a screening and diagnostic tool as it does not rely on X-ray
exposure and allows direct visualisation of all the swallowing
muscles.
There is a need for both increased reporting from
patients and increased specific questioning from clin-
icians. This will help identify the symptoms at an
earlier stage, promote earlier intervention and aware-
ness and lead to further studies on treatments, and in
turn a consensus on the most appropriate treatment.
Conservative treatments may be effective if diagnosed
in the early phase and therefore early diagnosis of
dysphagia is paramount.11,15,41
Invesgaon of dysphagia 
in IBM
Clinical acumen 





Figure 1 Investigation paradigm in IBM.
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Treatment Strategies for Dysphagia
in IBM
Currently, treatment options for IBM can be broadly cate-
gorized into non-invasive and invasive, refer to Figure 2.
Non-Invasive Treatment Options for
Dysphagia in IBM
Non-Invasive treatment options for dysphagia secondary to
IBM include compensatory as well as medical approaches.
Exercise therapy is the only proven therapy to delay the
progression of IBM in limb muscles.42–45 A case report by
Malandraki and colleagues outlines a lingual strengthening
program that was suggested to be effective in maintaining
disease-related lingual strength loss and swallowing.46 The
Mendelsohn manoeuvre is a compensatory manoeuvre asso-
ciated with peak pharyngeal contraction, contraction duration
and longer bolus transit time.4 It increases the extent and
duration of laryngeal elevation and thereby increases the
duration and width of UES opening47. The Mendelsohn
manoeuvre was useful for helping some IBM patients main-
tain a stable weight and continue eating without
aspiration28,48 but is likely to be more helpful early in the
disease course while there is still some remaining muscle
function. However, many patients find the Mendelsohn man-
oeuvre difficult to complete and therefore compliance is an
issue.7,49 The insidious decline in swallowing function and
delayed presentation of dysphagia inmany IBM patients may
mean that it is already too late for conservative management
by the time it is detected.
There are no established pharmacological treatments for
dysphagia in IBM, although multiple studies have investi-
gated the use of intravenous immunoglobulin (IVIG). The
use of IVIG has been reported to coincide with some
improvement of dysphagia.31,50–56 A randomised controlled
trial by Dalakas et al53 showed an improvement in the
swallowing function in IVIG randomised IBM patients
compared with placebo.53 Similarly, Dobloug and his col-
leagues found short-term beneficial effects in severe dys-
phagia following IVIG treatment in a selected number of
IBM patients.54 In a case series, Murata and his colleagues
described a cohort that were previously unable to eat half
solid meals improved after IVIG administration.31 The
treatment efficacy, however, lasted 2 months.31 Cherin
et al followed four IBM patients with dysphagia who were
treated with IVIG and they reported an improvement of
swallowing after the third treatment.50
Studies have also investigated the use of subcutaneous
immunoglobulin to achieve long-lasting stabilization of
swallowing. A case report described the use of subcuta-
neous immunoglobulin as beneficial on an IBM patient.57
The improvement in swallowing following subcutaneous
immunoglobulin was also supported by the results of
a case series by Cherin and colleagues who demonstrated
improvement in muscle strength and resolution of dyspha-
gia symptoms in six cases.33
A commonality of all the studies that investigated the
use of immunoglobulin is that the patient cohort had
moderate or severe IBM and the beneficial effect was
reported in the short-term. Future studies should include
patients with early (newly diagnosed) IBM as this group
might be more responsive to immunoglobulin treatment
than those with advanced disease. There is still no con-
sensus globally on the role of immunoglobulin for the
















Figure 2 Summary of current treatment strategies for dysphagia in IBM patients.
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further high quality longer trials of immunoglobulin, and
the development of novel therapies to help treat this dis-
abling complication of IBM.
Invasive Treatment Options for Dysphagia
in IBM
Currently, invasive options are the most effective in treat-
ing dysphagia in IBM and are utilised when severe weight
loss and malnutrition are apparent.58
Balloon dilation of the pharyngoesophageal segment
decreases cricopharyngeal retraction and therefore keeps
the UES open. It is simple, minimally invasive and low-
cost. In a study of three IBM patients with dysphagia, 3
months of balloon dilation therapy used in conjunction
with IVIG resulted in patients previously unable to eat
regular meals, eating regular meals for at least one-year
post-therapy.31 These results contrast to Oh and his col-
leagues who performed a retrospective review of 26
patients and found that dilations were performed in one-
quarter of the patients and that two-thirds did not note any
benefit despite a number of repeated procedures.28
Botulinum toxin injection to the UES/cricopharyngeus
muscle was found to be effective in alleviating dysphagia
and reducing the rate of aspiration.4,15,24,28,58,59 Initially
trialed by Schneider and his colleagues in 1994,58 botuli-
num toxin was found to improve swallowing in all but 2 of
7 patients with cricopharyngeus muscle dysfunction.
Following this study, Liu et al59 described two IBM
patients who experienced beneficial effects on their dys-
phagia with durations of 6.4 to 8 months post-injection.59
Similarly, Di Pede et al combined botulinum toxin injec-
tions with rehabilitation and found improvement of swal-
lowing in three IBM patients.24 Botulinum toxin was
beneficial in Schrey et al study whereby repetitive injec-
tions of BoNT-A alleviated dysphagia in 12 patients.15 The
injections not only showed symptomatic improvement in
all 12 patients but completely eliminated aspiration in
seven of the 12 patients who demonstrated aspiration pre-
the injection.15 Preliminary results from a recent abstract
also demonstrate the beneficial effect of botulinum toxin
injections in IBM patients.60 Botulinum toxin injection is
associated with improved quality of life according to
a study by Kelly and his colleagues.61
Conversely, Oh et al4 described two IBM patients for
whom botulinum toxin injection was not effective at alle-
viating dysphagia. The doses of the toxin and the injection
technique, however, were not reported.4,28 An overall
disadvantage of the botulinum toxin is that it requires
repeated administration and the potential complication of
hoarseness or an exacerbation of dysphagia rather than
relief62 due to the diffusion of botulinum toxin to the
adjacent proximal pharynx.
The combination of balloon dilation and BoNT-A,
however, has been suggested to improve dysphagia over
the long term. In a retrospective study by Parres in 201563
patients who had balloon dilations were compared to
patients who had dilation with concurrent Botox injection
into the cricopharyngeus. The combination of dilation and
BoNT-A resulted in transient worsening of dysphagia fol-
lowed by improvement lasting 4–5 months.63 Larger stu-
dies are needed to investigate whether the combination of
the two approaches can augment one another.
The most invasive treatment method is cricopharyngeal
myotomy. It has been reported to provide relief for a large
percentage of patients.12,29,64–66 Around 60% of patients with
IBMwho undergomyotomy report benefit.2,28 Themyotomy
divides the cricopharyngeus muscle and redistributes pres-
sure such that bolus propulsion out of the pharynx requires
less pressure.67 It is effective albeit a non-reversible method
and is not suitable for all IBM patients. Langdon and her
colleagues suggest that myotomy is only appropriate treat-
ment for dysphagia based on the aetiology of the swallow.14
They specify that in patients where laryngeal excursion,
intrabolus pressure, tongue and pharyngeal propulsion are
adequate but the UES fails to relax are the most likely benefit
from a myotomy.14 Conversely, IBM patients that have
abnormal hyolaryngeal excursion or a hyporeflexic sphincter
will not benefit from a cricopharyngeal myotomy.14 Another
patient group that cricopharyngeal myotomy is not suitable
for is those with hiatus hernia. A case report illustrated an
IBM patient with dysphagia and incidental finding of hiatus
hernia. Treatment of the dysphagia with a cricopharyngeal
myotomy, subsequently resulted in aspiration pneumonia and
assisted ventilation post-operation.68
Another invasive option to treat the burden of eating
and malnutrition associated with severe dysphagia in IBM
with the use of a percutaneous endoscopic gastrostomy
(PEG) feeding tube. PEG requires an invasive endoscopic
procedure with insertion of the feeding tube through the
anterior abdominal wall, an operation which occasionally
can be complicated by bleeding, peritonitis or perforation
of other abdominal organs.69 In the Oh et al study PEG
placement occurred in about one-quarter of IBM patients
without clear effect on outcome due to the severity of the
disease.28 The PEG placement does not always replace
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oral intake or eliminate the risk of aspiration. The 6
patients that received a PEG placement in the Oh et al
study died during the course of the study due to
aspiration.28 The role of the PEG tube in IBM is unclear
at this stage and PEG seems to be used as a last resort for
refractory dysphagia in IBM.21,56,63 There is a need for
studies that investigate its use earlier in the disease course.
In summary, the current evidence suggests that mini-
mally invasive and invasive methods are more effective
long term than non-invasive in terms of improving swal-
lowing as an endpoint. Minimally invasive methods should
be considered first-line to improve swallowing in IBM
patients with moderate-severe dysphagia. If dysphagia is
not alleviated by balloon dilation or botox or
a combination of the two, the patient may benefit from
a more invasive method, such as cricopharyngeal myot-
omy. The benefits of treating debilitating and severe dys-
phagia outweigh the risks of the invasive methods as the
treatment is likely to significantly improve the quality of
life of the patient.
Significance of Addressing
Dysphagia in IBM Patients
Swallowing is an essential function of the body and impor-
tant for human life and socialization. An inability to swal-
low therefore has significant effects on social, emotional
and medical aspects of IBM patients.
IBM patients who have dysphagia isolate themselves
more, avoid eating out with other people due to embarrass-
ment and the fact they may require more assistance during
meals.70 There are adverse effects of dysphagia on self-
esteem, socialization and enjoyment of life.70 The quality
of life of IBM patients with dysphagia is significantly
impaired and they become more socially isolated.
Complications of dysphagia include aspiration leading
to chest infection and pneumonia, malnutrition, dehydra-
tion and increased length of hospital stay and re-admission
to hospital.71 Pneumonia especially is a frequent compli-
cation of, occurring in all patients diagnosed with dyspha-
gia secondary to IBM.28,72 A strong relationship has been
established between laryngeal penetration/aspiration and
pneumonia.73 As a result, dysphagia is directly associated
with an increased risk of aspiration pneumonia and
death.72,73 Further, nutritional deficits in protein increase
the breakdown of muscle, thus contributing to the progres-
sion of this disease.
Conclusions and Future Directions
Due to the complex and insidious nature of IBM, the
diagnosis and management of dysphagia is challenging
and more research is required to further characterise and
manage dysphagia in patients with IBM. Detailed imaging
and functional studies may yield more information on the
underlying mechanisms in the musculature of the orophar-
ynx and lead to more specific therapies, and better-
designed clinical trials to test these.
There is a need to develop more effective forms of treat-
ment that are non-invasive in nature and that will delay or
stop the progression of dysphagia, particularly when intro-
duced early in the course of the disease. A commonality
between all current treatment modalities is that they are
most effective when dysphagia is diagnosed early.
Therefore, a strong emphasis should be placed on the screen-
ing, diagnosis and investigation of dysphagia during the early
stages of the disease – ideally at diagnosis because the delay-
to diagnosis remains around 5 years.3,12,74–76 Most IBM
patients are unaware of the potential sinister significance of
dysphagia as a symptom or the implications of dysphagia on
their health, wellbeing and social life. Some IBM patients
accept dysphagia as an untreatable part of aging and the
disease process and therefore more emphasis should be
placed on educating patients so they know to report early
when it is only a minor issue, as this will form a vital part of
the overall treatment strategy. Clinicians should systemati-
cally screen for swallowing function at each appointment
using the questions suggested by Cox et al.11
The ultimate treatment goal of dysphagia in IBM
patients is to prevent aspiration and its related conse-
quences, maintain nutrition and hydration and to improve
quality of life for patients.
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